LDT(Laboratory Developed Tests) 시장 규모, 점유율, 동향 분석 리포트 : 기술별, 용도별, 지역별, 부문별 예측(2024-2030년)

Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics), By Application (Oncology, Nutritional & Metabolic Disease), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,530,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,964,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,831,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

LDT(Laboratory Developed Tests) 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 LDT(Laboratory Developed Tests) 개발 시장 규모는 2030년까지 198억 5,000만 달러에 달하며, 2024-2030년의 CAGR은 7.05%로 확대할 것으로 예측됩니다.

이 산업의 성장은 만성질환, 유전성 질환, 감염성 및 자가면역질환의 유병률 증가, 건강한 삶에 대한 사람들의 인식이 높아짐에 따라 성장하고 있습니다. LDT(Laboratory Developed Tests)는 분자진단학에서 가장 일반적으로 사용되는데, 여기에는 유전학 외에도 다양한 화학물질을 표적으로 하는 검사가 포함됩니다.

예를 들어 2022년 7월 퀘스트 진단(Quest Diagnostics)은 원숭이 수두 바이러스 감염 진단을 위한 실험실 기반 분자진단 테스트를 출시했습니다. 또한 면역 분석은 새로운 테스트의 개발로 인해 엄청난 채택률과 수용성을 얻고 있습니다. 예를 들어 2021년 12월 OPKO Health, Inc.는 환자의 나이, 생검력, 직장수지검사 결과를 고려하여 4개의 면역측정법을 하나의 수치 점수로 통합한 LDT인 4Kscore 검사에 대한 FDA 승인을 발표했습니다. FDA의 승인은 필요하지 않지만, 엄격한 검증 절차를 거쳐야 합니다. 그러나 전 세계에서 암의 유병률 증가는 산업 성장을 가속하는 중요한 요인입니다.

GLOBOCAN에 따르면 2020년 전 세계에서 새로 발생하는 암 환자는 1,930만 명으로 추산되며, 그 중 유방암 환자는 230만 명으로 추정됩니다. 폐암은 암 환자 중 가장 많은 사망 원인으로, 이 분야는 더 빠르고 정확한 진단 툴에 대한 미충족 수요가 증가하고 있으며, 2021년 1월 영국 체외진단약 협회는 영국 NHS 잉글랜드에 암 분야 분자진단약 위탁 프레임워크를 개발할 것을 요청했습니다. 주요 기업은 더 높은 업계 점유율을 확보하기 위해 제품 출시와 지역적 확장에 집중하고 있습니다. 예를 들어 2022년 5월 가디언트 헬스(Guardant Health)는 45세 이상 성인 집단에서 대장암의 조기 징후를 감지할 수 있는 LDT로 사용할 수 있는 혈액 검사 '쉴드(Shield)'를 출시하였습니다.

LDT(Laboratory Developed Tests) 시장 보고서 하이라이트 :

• 분자진단 기술 부문은 2023년 전체 매출에서 가장 큰 비중을 차지하며 업계를 지배했습니다.
• 이 부문의 성장은 많은 질병에 대한 진단 검사를 제공해야 할 필요성이 높아졌기 때문입니다.
• 암 용도는 암 유병률 증가로 인해 예측 기간 중 크게 성장할 것으로 예상됩니다.
• 이 시장은 대상자 증가하는 수요에 대응할 수 있는 혁신적인 서비스 도입으로 인해 크게 성장할 것으로 예상됩니다.
• 북미는 새로운 LDT 제품 출시와 노인 인구 증가에 따른 진단 툴에 대한 높은 수요로 인해 2023년 업계를 지배했습니다.

목차

제1장 LDT(Laboratory Developed Tests) 시장 : 조사 방법과 범위

제2장 LDT(Laboratory Developed Tests) 시장 : 주요 요약

• 시장 전망
• 부문 전망
• 경쟁 인사이트

제3장 LDT(Laboratory Developed Tests) 시장 : 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
• LDT(Laboratory Developed Tests) 시장 분석 툴

제4장 LDT(Laboratory Developed Tests) 시장 : 기술 추정·동향 분석

• 기술의 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 세계의 LDT(Laboratory Developed Tests) 시장, 기술별 전망
• 2018-2030년 시장 규모와 예측·동향 분석

제5장 LDT(Laboratory Developed Tests) 시장 : 용도 추정·동향 분석

• 용도의 시장 점유율, 2023년 및 2030년
• 부문 대시보드
• 세계의 LDT(Laboratory Developed Tests) 시장, 용도별 전망
• 2018-2030년 시장 규모와 예측·동향 분석

제6장 LDT(Laboratory Developed Tests) 시장 : 지역 추정·동향 분석

• 지역의 시장 점유율 분석, 2023년 및 2030년
• 지역의 시장 대시보드
• 세계의 지역의 시장 스냅숏
• 2018-2030년 시장 규모와 예측·동향 분석
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • Quest Diagnostics Incorporated.
  • 23andMe, Inc.
  • Abbott
  • Guardant Health
  • NeoGenomics Laboratories.
  • QIAGEN
  • Siemens Healthineers AG
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.

KSA

영문 목차

영문목차

Laboratory Developed Tests Market Growth & Trends:

The global laboratory developed tests market size is expected to reach USD 19.85 billion by 2030, expanding at a CAGR of 7.05% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the industry is attributed to the increasing prevalence of chronic and genetic diseases, infectious & autoimmune diseases, and rising awareness among the population about healthy living. The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment. LDTs are most typically employed in molecular diagnostics, which includes tests that target a variety of different chemicals in addition to genetics.

For instance, in July 2022, Quest Diagnostics launched a lab-based molecular diagnostic test for the diagnosis of monkeypox virus infections. Moreover, immunoassay is gaining immense adoption and acceptability with the development of novel tests. For instance, in December 2021, OPKO Health, Inc., announced the FDA approval of the 4Kscore test, an LDT in which, four immunoassays are combined into a single numerical score that takes into account the patient's age, biopsy history, and the results of a digital rectal exam. Although LDTs do not require FDA approval as they are not marketed to others, they need to go through rigorous validation procedures. However, the increasing global prevalence of cancer is a key factor driving the industry's growth.

According to GLOBOCAN, in 2020, there were an estimated 19.3 million new cancer cases globally, out of which, 2.3 million were breast cancer cases. Lung cancer was the most common cause of death among cancer patients, representing an unmet need for faster and more accurate diagnostic tools in the segment. In January 2021, the British In Vitro Diagnostics Association urged NHS England for the development of a commissioning framework for molecular diagnostics in oncology. Key players focus on product launches and geographical expansion to gain a higher industry share. For instance, in May 2022, Guardant Health launched Shield, a blood test that is available as an LDT for the detection of early signs of colorectal cancer in the adult population aged above 45 years

Laboratory Developed Tests Market Report Highlights:

• The molecular diagnostic technology segment dominated the industry and accounted for the largest share of the overall revenue in 2023
• The segment growth was attributed to the increased need to provide diagnostics tests for a number of diseases
• The oncology application segment is expected to grow lucratively over the forecast period due to the increasing prevalence of cancer
• The market is expected to grow significantly owing to the introduction of innovative services that can address the growing demands of the target audience
• North America dominated the industry in 2023 owing to the introduction of novel LDT products and the high demand for diagnostics tools with the increasing geriatric population

Table of Contents

Chapter 1. Laboratory Developed Tests Market: Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Laboratory Developed Tests Market: Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Laboratory Developed Tests Market: Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing demand for in vitro diagnostic tests that are currently unavailable in the market
    • 3.2.1.2. Increasing demand for development of personalized medicine
    • 3.2.1.3. No requirement for any regulatory approval
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with the laboratory-developed test
    • 3.2.2.2. Efficacy and safety issues related to LDT
• 3.3. Laboratory Developed Tests (LDT) Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Laboratory Developed Tests (LDT) Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Laboratory Developed Tests (LDT) Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Immunoassays
    • 4.4.1.1. Immunoassays market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Hematology and Coagulation
    • 4.4.2.1. Hematology and coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Molecular Diagnostics
    • 4.4.3.1. Molecular diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Microbiology
    • 4.4.4.1. Microbiology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Clinical Chemistry
    • 4.4.5.1. Clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Histology/Cytology
    • 4.4.6.1. Histology/Cytology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.7. Flow Cytometry
    • 4.4.7.1. Flow Cytometry market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.8. Mass Spectroscopy
    • 4.4.8.1. Mass spectroscopy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.9. Others
    • 4.4.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Laboratory Developed Tests (LDT) Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Laboratory Developed Tests (LDT) Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Oncology
    • 5.4.1.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Genetic Disorders/Inherited Disease
    • 5.4.2.1. Genetic disorders/Inherited disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Infectious & Parasitic Diseases
    • 5.4.3.1. Infectious & parasitic diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Immunology
    • 5.4.4.1. Immunology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. Endocrine
    • 5.4.5.1. Endocrine market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. Nutritional & Metabolic Disease
    • 5.4.6.1. Nutritional & metabolic disease market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.7. Cardiology
    • 5.4.7.1. Cardiology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.8. Mental/Behavioral Disorder
    • 5.4.8.1. Mental/Behavioral disorder market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.9. Pediatrics-specific Testing
    • 5.4.9.1. Pediatrics-specific testing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.10. Hematology/General Blood Testing
    • 5.4.10.1. Hematology/General blood testing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.11. Bodily Fluid Analysis
    • 5.4.11.1. Bodily fluid analysis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.12. Toxicology
    • 5.4.12.1. Toxicology market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.13. Other Diseases
    • 5.4.13.1. Other diseases market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Laboratory Developed Tests (LDT) Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Quest Diagnostics Incorporated.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. 23andMe, Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Abbott
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Guardant Health
    • 7.3.7.1. Company overview
    • 7.3.7.2. Product benchmarking
    • 7.3.7.3. Strategic initiatives
  • 7.3.8. NeoGenomics Laboratories.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. QIAGEN
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Siemens Healthineers AG
    • 7.3.10.1. Company overview
    • 7.3.10.2. Product benchmarking
    • 7.3.10.3. Strategic initiatives
  • 7.3.11. Illumina, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Product benchmarking
    • 7.3.11.3. Strategic initiatives
  • 7.3.12. F. Hoffmann-La Roche Ltd.
    • 7.3.12.1. Company overview
    • 7.3.12.2. Product benchmarking
    • 7.3.12.3. Strategic initiatives

관련자료